tiprankstipranks

Kevin Bitterman Insider Profile

4 Followers
Kevin Bitterman, Director at Genocea Biosciences, holds 926.83K shares in Disc Medicine (Ticker: IRON), holds 2.52M shares in Akero Therapeutics (Ticker: AKRO), holds 4.16M shares in Editas Medicine (Ticker: EDIT). Most recently, Kevin Bitterman Sold ― shares of Disc Medicine on Mar 07, 2024 for an estimated value of 1.92M.
tipranks
Kevin Bitterman

Kevin Bitterman
Genocea Biosciences (GNCAQ)
Director

Ranked #84,850 out of 98,743 Corporate Insiders

Profitable Transactions

44%
7 out of 16 Profitable Transactions

Average Return

-15.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$101M
52.41%
26.87%
20.68%
0.03%
A breakdown of Kevin Bitterman's holdings

Insider Roles

Akero Therapeutics
(AKRO)
Director
Disc Medicine
(IRON)
Director
Editas Medicine
(EDIT)
Director, Ten Percent Owner
Genocea Biosciences
(GNCAQ)
Director
Roles that Kevin Bitterman holds in companies

Most Profitable Insider Trade

Stock:
Disc Medicine
(IRON)
Rating:Informative Sell
Date:Jan 25, 2024 - Today
Return:+52.90%
The most profitable trade made by Kevin Bitterman

Kevin Bitterman's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Genocea Biosciences
Feb 11, 2014
Director
Uninformative Buy
$31.93K
Editas Medicine
May 24, 2017
Director, Ten Percent Owner
Informative Sell
17.00M
$20.93M
Akero Therapeutics
Jun 03, 2021
Director
Uninformative Sell
459.61K
$53.04M
Disc Medicine
Mar 07, 2024
Director
Informative Sell
1.92M
$27.19M
List of latest transactions for each holding click on a transaction to see Kevin Bitterman's performance on stock

Kevin Bitterman insider profile FAQ

What is the percentage of profitable transactions made by Kevin Bitterman?
The percentage of profitable transactions made by Kevin Bitterman is 44%.
    What is the average return per transaction made by Kevin Bitterman?
    The average return per transaction made by Kevin Bitterman is -15.10%.
      What stocks does Kevin Bitterman hold?
      Kevin Bitterman holds: GNCAQ, EDIT, AKRO, IRON stocks.
        What was Kevin Bitterman’s latest transaction?
        Kevin Bitterman latest transaction was an Informative Sell of $1.92M.
          What was Kevin Bitterman's most profitable transaction?
          Kevin Bitterman’s most profitable transaction was an Informative Sell of IRON stock on January 25, 2024. The return on the trade was 52.90%.
            What is Kevin Bitterman's role in Genocea Biosciences?
            Kevin Bitterman's role in Genocea Biosciences is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.